Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae

Sarah M. Bartsch; Susan S. Huang; Kim F. Wong; Rachel B. Slayton; James A. McKinnell; Daniel F. Sahm; Krystyna Kazmierczak; Leslie E. Mueller; John A. Jernigan; Bruce Y. Lee

doi:10.1128/JCM.00635-16

Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae

Sarah M. Bartsch, Susan S. Huang, Kim F. Wong, Rachel B. Slayton, James A. McKinnell, Daniel F. Sahm, Krystyna Kazmierczak, Leslie E. Mueller, John A. Jernigan, Bruce Y. Lee

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Delays often occur between CLSI and FDA revisions of antimicrobial interpretive criteria. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model, we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoints might have resulted in 1,821 additional carriers in Orange County, CA, an outcome that could have been avoided by identifying CRE and initiating contact precautions. Policy makers should aim to minimize the delay in the adoption of new breakpoints for antimicrobials against emerging pathogens when containment of spread is paramount; delays of<1.5 years are ideal.

Original language	English (US)
Pages (from-to)	2757-2762
Number of pages	6
Journal	Journal of clinical microbiology
Volume	54
Issue number	11
DOIs	https://doi.org/10.1128/JCM.00635-16
State	Published - Nov 2016

ASJC Scopus subject areas

Microbiology (medical)

Access to Document

10.1128/JCM.00635-16

Cite this

Bartsch, S. M., Huang, S. S., Wong, K. F., Slayton, R. B., McKinnell, J. A., Sahm, D. F., Kazmierczak, K., Mueller, L. E., Jernigan, J. A., & Lee, B. Y. (2016). Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae. Journal of clinical microbiology, 54(11), 2757-2762. https://doi.org/10.1128/JCM.00635-16

Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae. / Bartsch, Sarah M.; Huang, Susan S.; Wong, Kim F. et al.
In: Journal of clinical microbiology, Vol. 54, No. 11, 11.2016, p. 2757-2762.

Research output: Contribution to journal › Article › peer-review

Bartsch, SM, Huang, SS, Wong, KF, Slayton, RB, McKinnell, JA, Sahm, DF, Kazmierczak, K, Mueller, LE, Jernigan, JA & Lee, BY 2016, 'Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae', Journal of clinical microbiology, vol. 54, no. 11, pp. 2757-2762. https://doi.org/10.1128/JCM.00635-16

@article{fa18ac3a399b488e8b9efb2b55eefed5,

title = "Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae",

abstract = "Delays often occur between CLSI and FDA revisions of antimicrobial interpretive criteria. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model, we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoints might have resulted in 1,821 additional carriers in Orange County, CA, an outcome that could have been avoided by identifying CRE and initiating contact precautions. Policy makers should aim to minimize the delay in the adoption of new breakpoints for antimicrobials against emerging pathogens when containment of spread is paramount; delays of<1.5 years are ideal.",

author = "Bartsch, {Sarah M.} and Huang, {Susan S.} and Wong, {Kim F.} and Slayton, {Rachel B.} and McKinnell, {James A.} and Sahm, {Daniel F.} and Krystyna Kazmierczak and Mueller, {Leslie E.} and Jernigan, {John A.} and Lee, {Bruce Y.}",

year = "2016",

month = nov,

doi = "10.1128/JCM.00635-16",

language = "English (US)",

volume = "54",

pages = "2757--2762",

journal = "Journal of clinical microbiology",

issn = "0095-1137",

publisher = "American Society for Microbiology",

number = "11",

}

TY - JOUR

T1 - Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae

AU - Bartsch, Sarah M.

AU - Huang, Susan S.

AU - Wong, Kim F.

AU - Slayton, Rachel B.

AU - McKinnell, James A.

AU - Sahm, Daniel F.

AU - Kazmierczak, Krystyna

AU - Mueller, Leslie E.

AU - Jernigan, John A.

AU - Lee, Bruce Y.

PY - 2016/11

Y1 - 2016/11

N2 - Delays often occur between CLSI and FDA revisions of antimicrobial interpretive criteria. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model, we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoints might have resulted in 1,821 additional carriers in Orange County, CA, an outcome that could have been avoided by identifying CRE and initiating contact precautions. Policy makers should aim to minimize the delay in the adoption of new breakpoints for antimicrobials against emerging pathogens when containment of spread is paramount; delays of<1.5 years are ideal.

AB - Delays often occur between CLSI and FDA revisions of antimicrobial interpretive criteria. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model, we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoints might have resulted in 1,821 additional carriers in Orange County, CA, an outcome that could have been avoided by identifying CRE and initiating contact precautions. Policy makers should aim to minimize the delay in the adoption of new breakpoints for antimicrobials against emerging pathogens when containment of spread is paramount; delays of<1.5 years are ideal.

UR - http://www.scopus.com/inward/record.url?scp=84992418421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992418421&partnerID=8YFLogxK

U2 - 10.1128/JCM.00635-16

DO - 10.1128/JCM.00635-16

M3 - Article

C2 - 27582516

AN - SCOPUS:84992418421

SN - 0095-1137

VL - 54

SP - 2757

EP - 2762

JO - Journal of clinical microbiology

JF - Journal of clinical microbiology

IS - 11

ER -

Impact of delays between clinical and laboratory standards institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this